Arcus biosciences announces clinical trial collaboration agreement to evaluate casdatifan in combination with volrustomig in renal cell carcinoma

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with astrazeneca (lse/sto/nasdaq: azn) to evaluate casdatifan (ab521), arcus's investigational hif-2a inhibitor, in combination with volrustomig, astrazeneca's investigational pd-1/ctla-4 bispecific antibody, in patients wi.
RCUS Ratings Summary
RCUS Quant Ranking